Palmar Fibromatosis Epidemiology Forecast 2025-2034

A 2020 meta-analysis encompassing 85 studies with over 6.6 million individuals estimated that 8.2% of the global population is affected by palmar fibromatosis (also known as Dupuytren’s disease). The palmar fibromatosis epidemiology forecast by Expert Market Research indicates that males are more susceptible to develop the condition as compared to females.

Palmar Fibromatosis Epidemiology Forecast Report Coverage

Expert Market Research's “Palmar fibromatosis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of palmar fibromatosis. It projects the future incidence and prevalence rates of palmar fibromatosis cases across various populations. The study covers age, gender, and type as major determinants of the palmar fibromatosis population. The report highlights patterns in the prevalence of palmar fibromatosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on palmar fibromatosis epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Palmar Fibromatosis Understanding: Disease Overview

Palmar fibromatosis, or Dupuytren’s Disease, is a fibroproliferative disorder affecting the palmar fascia, marked by abnormal collagen deposition and myofibroblast proliferation. The disease begins with painless nodules in the palm, progressing to fibrous cords that tether the fingers, leading to fixed flexion contractures and impaired hand function. Histologically, it involves myofibroblast activity, excessive type III collagen accumulation, and altered growth factor signaling. Without treatment, progressive contractures may significantly impair daily activities, making early recognition and intervention essential for preserving hand mobility.

Palmar Fibromatosis Epidemiology Perspective

The palmar fibromatosis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the palmar fibromatosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for palmar fibromatosis and its trends. The palmar fibromatosis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• A 2024 primary-care registry analysis reported a point prevalence of 1.99% for Palmar Fibromatosis, reflecting its persistent burden in general practice populations.
• The annual incidence in the same cohort was 1.41-1.72 cases per 1,000 person-years, indicating a consistent rate of new diagnoses over time.
• Age-stratified analyses (between 2020-2024) indicate that the incidence peaks between 61 and 80 years, with a consistently higher prevalence observed in males across all study cohorts.

Country-wise Palmar Fibromatosis Epidemiology Segment

The palmar fibromatosis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Recent epidemiological analyses have highlighted a significant rise in palmar fibromatosis burden across the United States. Between 2016 and 2022, a comprehensive claims dataset identified 119,793 diagnosed cases, with numbers steadily increasing to approximately 22,711 cases in 2022. Experts attribute this trend to aging demographics, improved diagnostic accuracy, and growing disease awareness among both patients and clinicians. These findings emphasize the importance of enhanced surveillance systems and strategic healthcare planning to effectively manage the expanding clinical and surgical needs associated with Dupuytren’s disease.

Palmar Fibromatosis: Treatment Overview

Treatment for palmar fibromatosis aims to restore hand function and prevent further contracture progression. Conservative approaches include physiotherapy and splinting in early stages. For significant functional impairment, minimally invasive options such as collagenase clostridium histolyticum injections or needle aponeurotomy are widely used. Surgical interventions, such as limited fasciectomy or dermofasciectomy, remain the gold standard for advanced disease with severe contractures. Recurrence rates vary, necessitating long-term follow-up and postoperative rehabilitation to optimize outcomes and maintain functional range of motion.

Key Questions Answered

• What are the key findings of palmar fibromatosis epidemiology in the 8 major markets?
• What will be the total number of patients with palmar fibromatosis across the 8 major markets during the forecast period?
• What was the country-wise palmar fibromatosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of palmar fibromatosis during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of palmar fibromatosis during the forecast period of 2025-2034?
• What are the currently available treatments for palmar fibromatosis?
• What are the disease risks, signs, symptoms, and unmet needs of palmar fibromatosis?

Scope of the Palmar Fibromatosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of palmar fibromatosis based on several factors.
• Palmar Fibromatosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The palmar fibromatosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.